A 337 - Klus Pharma
Alternative Names: A-337 - Klus PharmaLatest Information Update: 26 Feb 2024
At a glance
- Originator Klus Pharma
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Cancer
Most Recent Events
- 19 Jan 2024 A 337 - Klus Pharma is available for licensing as of 19 Jan 2024. https://www.kluspharma.com/contact
- 19 Jan 2024 Phase-I clinical trials in Cancer in China (Parenteral) (Klus Pharma pipeline, January 2024)
- 19 Jan 2024 Klus Pharma plans combination clinical studies in Cancer (Parenteral) (Klus Pharma pipeline, January 2024)